Form D · Biotechnology
Adaptimmune Ltd
Abingdon, Oxfordshire, X0 · CIK 0001621227
Offering snapshot reported Oct 2, 2014 · SEC filing
- Reported sold
- $104M Offering amount: $104M
- Investors reported
- 22 Form D · investor count
- Minimum accepted
- $1 Reported outside-investor minimum
- First sale
- Sep 23, 2014 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 2, 2014 | Initial | $103,809,789 | No comparison | 22 | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-225667
Series A Preferred Shares
Source: Form D, filed Oct 2, 2014. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ali Behbahani | Director |
| Dr. Jonathan Knowles | Director |
| Ian Laing | Director |
| David Mott | Director |
| James Noble | Director, Executive |
| Elliott Sigal | Director |
| Peter Thompson | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
91 Park Drive Milton Park
Abingdon, Oxfordshire, X0, OX14 4RY
Abingdon, Oxfordshire, X0, OX14 4RY